The thought of bigger markets than the aged care sector has been getting me revved up since I linked that Harvard Medical news this morning
FWIW I think that the new consortium to study pain may have significance for Painchek even though dementia is not mentioned. ( here’s the link again
https://hms.harvard.edu/news/stopping-pain)
- It’s about ‘transforming the treatment of pain’
- It will use “experimental and artificial intelligence-driven approaches”
- It’s led by researchers from Harvard Medical School and Boston Children’s Hospital ( Painchek was showcased by Philips to the relevant people from both facilities last month )
- ..with collaborators from Massachusetts Institute of Technology (MIT) and the Max Planck Institute for Medical Research in Germany.
It may be too long a bow to draw - especially as it does not have FDA approval yet, but if the technology is more accurate than any other method for screening babies in pain ( as it
is according to Phillip Daffas on his third Phil Dyer video last month) then why not adults too? And it might not need to be approved because this is a test situation?
Painchek use in the scientific research by STOP PAIN could give instant feedback on the efficacy of drugs being tested ....maybe before the subject even realises a change?
And the consortium will be funded by the US Military - which is also huge for painchek if it is involved ?
( “DARPA cooperative agreement includes funding of up to $23,378,281.” )
To add more grist to the non-dementia use mill, Harvard Medical School will be running a short program on ‘Evaluating and Treating Pain in June 2020’
https://painmedicine.hmscme.com/
On June 18, 2020 a workshop that looks as if it was designed to showcase Painchek.....
“Conducting Difficult Conversations with Pain Patients
Thursday evening, June 18
Strategies, problem-solving education, role play and practice
This workshop helps clinicians to better prepare for and conduct difficult conversations with frustrated, angry or upset paint patients and conversations about opioid use and discontinuation. Participants get guidance to improve the process, experience and outcome for these conversations, including:
- Approaches that yield a better understanding of the patient’s agenda
- Setting your goals for the conversation and how to prepare accordingly
- Avoiding common missteps
- Techniques that result in a better patient/provider rapport and dialog
- Best practices to leverage these difficult conversations to produce more productive paint management and improved functional outcomes”
?
Cheers
-
(20min delay)